Technical Analysis for BNTC - Benitec Biopharma Limited
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | -0.19% | |
Gapped Up | Strength | -0.19% | |
20 DMA Resistance | Bearish | 3.23% | |
Spinning Top | Other | 3.23% | |
Gapped Up | Strength | 3.23% | |
20 DMA Resistance | Bearish | 3.23% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 3.23% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 3.23% | |
Inside Day | Range Contraction | 3.23% | |
Fell Below 20 DMA | Bearish | 3.43% |
Alert | Time |
---|---|
20 DMA Support | about 3 hours ago |
10 DMA Support | about 3 hours ago |
Fell Below Previous Day's Low | about 3 hours ago |
Down 1% | about 3 hours ago |
Up 2% | about 3 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/12/2024
Benitec Biopharma Limited Description
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Biopharmaceutical Biology Pain Genetics Chemotherapy Small Cell Lung Cancer Genetic Engineering Hepatitis B Macular Degeneration Gene Expression Dystrophy Muscular Dystrophy Hepatitis C Huntington's Disease Wet Age Related Macular Degeneration HIV/Aids RNA Clinical Applications Retinitis Rna Interference Ai Technology Gene Silencing Retinitis Pigmentosa Chronic And Life Threatening Conditions Oculopharyngeal Muscular Dystrophy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.01 |
52 Week Low | 1.86 |
Average Volume | 16,626 |
200-Day Moving Average | 3.45 |
50-Day Moving Average | 3.91 |
20-Day Moving Average | 5.08 |
10-Day Moving Average | 5.09 |
Average True Range | 0.34 |
RSI (14) | 60.78 |
ADX | 45.33 |
+DI | 31.21 |
-DI | 12.30 |
Chandelier Exit (Long, 3 ATRs) | 4.92 |
Chandelier Exit (Short, 3 ATRs) | 5.21 |
Upper Bollinger Bands | 5.47 |
Lower Bollinger Band | 4.69 |
Percent B (%b) | 0.56 |
BandWidth | 15.42 |
MACD Line | 0.31 |
MACD Signal Line | 0.39 |
MACD Histogram | -0.0797 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.42 | ||||
Resistance 3 (R3) | 5.43 | 5.35 | 5.37 | ||
Resistance 2 (R2) | 5.35 | 5.28 | 5.34 | 5.35 | |
Resistance 1 (R1) | 5.24 | 5.23 | 5.30 | 5.23 | 5.34 |
Pivot Point | 5.16 | 5.16 | 5.19 | 5.15 | 5.16 |
Support 1 (S1) | 5.05 | 5.09 | 5.11 | 5.04 | 4.92 |
Support 2 (S2) | 4.97 | 5.04 | 4.96 | 4.91 | |
Support 3 (S3) | 4.86 | 4.97 | 4.89 | ||
Support 4 (S4) | 4.85 |